Lefit 25 Tablet contains Levosulpiride 25 mg, a selective dopamine D2 receptor antagonist primarily used in the treatment of gastrointestinal motility disorders and certain psychiatric conditions. Levosulpiride exerts prokinetic effects by enhancing gastric emptying and improving esophageal motility, making it effective in managing functional dyspepsia, gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS) with predominant dysmotility symptoms. Additionally, Levosulpiride has antipsychotic and antidepressant properties due to its dopaminergic modulation in the central nervous system, which may be beneficial in treating schizophrenia, dysthymia, and depression with associated gastrointestinal symptoms. Lefit 25 is typically administered orally, with dosage adjusted according to the clinical indication and patient response. Common adverse effects include mild extrapyramidal symptoms, hyperprolactinemia, and gastrointestinal disturbances such as nausea or diarrhea. Caution is advised in patients with a history of prolactin-dependent tumors, Parkinson’s disease, or severe renal impairment. Lefit 25 should be used under medical supervision, with periodic monitoring to assess therapeutic efficacy and detect potential side effects. It is contraindicated in hypersensitivity to Levosulpiride or related compounds. Lefit 25 offers a targeted therapeutic option for patients requiring modulation of dopaminergic pathways to alleviate both gastrointestinal and neuropsychiatric symptoms.